SCHEMBL19658176

SCHEMBL19658176

O=C(ON1C(=O)CCC1=O)[C@@H]1CCCC[C@H]1C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
MGLL Q99685 5/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18751699 1.00 TP53 (0.35) TP53CYP3A4MGLL
SCHEMBL20848195 0.96 MGLL (0.33) TP53CYP3A4MGLL
SCHEMBL18751705 0.96 MGLL (0.33) TP53CYP3A4MGLL
SCHEMBL19658181 0.92 MGLL (0.33) MGLL
SCHEMBL19658322 0.92 MGLL (0.33) MGLL
SCHEMBL18751704 0.92 MGLL (0.33) MGLL
SCHEMBL13366915 0.91 HTT (0.38)
SCHEMBL24102291 0.88 EPHX1 (0.43) MGLL
SCHEMBL21100434 0.85 MGLL (0.33) MGLL
SCHEMBL17776326 0.85 MGLL (0.33) MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689430-B2 Insulin receptor partial agonists MERCK SHARP & DOHME CORP. (US) 2020-06-23 US disclosed
US-20190177393-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2019-06-13 US disclosed
WO-2017205309-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190177393-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 TP53 3535/4885CYP3A4 2335/4885MGLL 2105/4885
US-10689430-B2 Insulin receptor partial agonists INSR, GPR119, IRS1 TP53 3535/4885CYP3A4 2335/4885MGLL 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.